Forbes contributors publish independent expert analyses and insights.
After losing nearly half its value from its 2021 highs, Pfizer stock (NYSE: PFE) now trades at about $25, presenting a potentially attractive value setup. As the company continues to adapt to a post-pandemic environment with normalized COVID-19 vaccine demand, its solid fundamentals and a compelling 6.9% dividend yield point to an interesting opportunity for long-term, risk-adjusted returns.
But, if you prefer upside with lower volatility than a single stock, consider the High Quality Portfolio. It has comfortably outperformed its blended benchmark — the S&P 500, Russell, and S&P MidCap indexes — with returns exceeding 91% since inception. Separately, see – Ethereum Play: BMNR Stock To $100?
Pfizer’s share decline mirrors the tough shift from pandemic-driven outperformance to steady-state operations. Revenues surged during COVID-19 on exceptional vaccine sales, creating difficult year-over-year comparisons. Current revenues of $64 billion are 36% below the 2021 peak of $101 billion, fueling investor caution about the post-pandemic growth path.
Recent results imply Pfizer has stabilized after the 2023 trough and returned to growth. While the three-year average remains negative due to COVID normalization, the latest momentum appears to be improving.
Pfizer’s profitability leads on key measures, signaling efficiency and pricing power:
This resilience through a challenging transition underscores operational strength. Management targets about $4.5 billion in net cost savings by end-2025, within a broader multi-year effort aiming for $7.7 billion in net savings by end-2027.
Pfizer’s balance sheet remains sound, with manageable leverage:
Leverage bears watching, but looks serviceable given robust cash generation and the industry’s typically steady cash flows.
History shows PFE can lag in stress periods:
Overall, PFE has exhibited amplified volatility in sell-offs, though recoveries have often been solid. For more, see our dashboard: Buy or Fear Pfizer stock?
Pfizer trades at notable discounts across multiple valuation measures:
These levels suggest the market is pricing in significant growth concerns, creating upside potential for patient investors.
Supporting factors include:
In short, Pfizer looks like a reasonable value play for investors comfortable with moderate execution risk. While growth has been uneven and downturn resilience below average, today’s valuation appears to more than reflect these issues.
We’re not arguing Pfizer is the sector’s best growth story — names like AbbVie and Eli Lilly lead there. But for value-oriented investors, Pfizer stands out.
Of course, we could be wrong, and the market may wait for clearer proof of a turnaround before re-rating the stock. For investors with a 3-5 year horizon, however, Pfizer could still deliver strong results. See, there is always meaningful risk in owning a single — or just a few — stocks. Consider the Trefis High Quality (HQ) Portfolio, a 30-stock collection that has comfortably outperformed the S&P 500 over the last four years — delivering better returns with less volatility, as shown in the HQ Portfolio performance metrics.
